Safety of secukinumab treatment in COVID-19 affected psoriatic patients

Dermatol Ther. 2021 Jan;34(1):e14710. doi: 10.1111/dth.14710. Epub 2021 Jan 3.

Authors

Cristina Mugheddu¹, Silvia Sanna¹, Laura Atzori¹, Franco Rongioletti¹

Affiliation

¹ Dermatology Clinic, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Antibodies, Monoclonal, Humanized / therapeutic use*
Arthritis, Psoriatic* / drug therapy
COVID-19*
Humans
SARS-CoV-2

Substances

Antibodies, Monoclonal, Humanized
secukinumab